Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 387 across all filing types
Latest filing 2020-09-22 Regulatory Filings
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings
2020-09-22 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Cardinal Capital Partners Inc. It announces a material change involving a business combination transaction (reverse takeover) with MindHealth Biomed Corp. The document includes detailed information about the transaction, the proposed changes to the board and management, shareholder meetings to approve the transaction, and other related corporate actions. The form and content indicate this is a regulatory announcement of a material corporate event rather than a full financial report or earnings release. It is not a full annual or interim report, nor a proxy solicitation or voting results announcement. The document is a formal regulatory filing reporting a material change event as required by securities regulations. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-09-17 English
News release - English.pdf
Regulatory Filings
2020-09-14 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-08-27 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2020-08-27 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by Cardinal Capital Partners Inc. It announces a material change involving a letter of intent for a reverse takeover transaction with MindHealth Biomed Corp. The document includes detailed information about the transaction, private placement financing, share consolidation, management changes, and conditions for closing. It is a regulatory filing reporting a significant corporate event (a reverse takeover and private placement) rather than a full annual or quarterly financial report, earnings release, or management discussion. The document is not a proxy solicitation, dividend notice, or audit report. It is a formal disclosure of a material change as required by securities regulations, which fits the category of Regulatory Filings (RNS). The length and detail confirm it is not a brief announcement or report publication notice. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-08-17 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.